Adma Biologics (ADMA) Exceeds Market Returns: Some Facts to Consider
The latest trading day saw Adma Biologics (ADMA) settling at $9.16, representing a +2.35% change from its previous close.
Adma Biologics (ADMA) Stock Falls Amid Market Uptick: What Investors Need to Know
Adma Biologics (ADMA) closed at $8.37 in the latest trading session, marking a -4.34% move from the prior day.
Adma Biologics (ADMA) Advances While Market Declines: Some Information for Investors
Adma Biologics (ADMA) concluded the recent trading session at $8.69, signifying a +1.4% move from its prior day's close.
3 Biotech Firms With Major Potential Catalysts in the Coming Months
As Big Pharma braces for a looming patent cliff that threatens billions in revenue, a different group of companies is chasing the opposite story: a single breakthrough that could define their future. For these smaller players, one strong trial readout or FDA approval can mean the difference between a breakout and a bust.
3 Biotech Firms With Major Potential Catalysts in the Coming Months
As Big Pharma braces for a looming patent cliff that threatens billions in revenue, a different group of companies is chasing the opposite story: a single breakthrough that could define their future. For these smaller players, one strong trial readout or FDA approval can mean the difference between a breakout and a bust.
Adma Biologics (ADMA) Dips More Than Broader Market: What You Should Know
The latest trading day saw Adma Biologics (ADMA) settling at $8.42, representing a -1.86% change from its previous close.
Adma Biologics (ADMA) Stock Dips While Market Gains: Key Facts
Adma Biologics (ADMA) closed the most recent trading day at $8.33, moving 1.83% from the previous trading session.
Adma Biologics (ADMA) Down 5.8% Since Last Earnings Report: Can It Rebound?
Adma Biologics (ADMA) reported earnings 30 days ago. What's next for the stock?
New Strong Sell Stocks for June 3rd
AOS, ADMA and AMTB have been added to the Zacks Rank #5 (Strong Sell) List on June 3rd, 2026.
ADMA Biologics: Longstanding Bull Hits The Reset Button After Murky Q1 Earnings
ADMA Biologics (ADMA) faces IVIG market headwinds, flat Q1 revenue, and reduced 2026 guidance, leading to a >50% YTD share price decline. ASCENIV's differentiated profile drove 28% YoY revenue growth and record utilization, partially offsetting BIVIGAM's 54% decline amid IVIG pricing pressure. Gross margin expanded to 71%, adjusted EBITDA rose 24% YoY, and strong cash generation supports resilience despite market disruption.
ADMA vs Intellia Therapeutics: Which Biotech Stock Is a Better Pick Now?
NTLA gains momentum after positive phase III data for its CRISPR therapy, while ADMA faces pricing and inventory pressure in IG markets.
Can Asceniv Help ADMA Navigate the Current IG Market Challenges?
ADMA faces IG pricing pressure and reduced 2026 guidance, but Asceniv demand remains strong amid resilient patient utilization.
